Portland, OR -- (SBWIRE) -- 05/22/2018 -- The Blood Plasma Derivatives Market was valued at $23,613 million in 2016, and is projected to reach $44,333 million at a CAGR of 9.3% from 2017 to 2023. Blood plasma is the liquid component of blood constituting of water along with plasma components such as immunoglobulin, electrolytes, glucose, clotting factors, electrolytes, and hormones. It plays a crucial role in maintaining the electrolyte and osmotic balance while preventing infection and blood disorders in the body. Plasma derivatives are the concentrates of specific proteins, which require pooling of plasma from large number of donors. For instance, they require more than hundred plasma donations to produce sufficient immunoglobulin to treat an immune-deficient patient for one year. They are obtained by the process of fractionation where protein concentrates are separated and then clinically used.

Market Dynamics

The growth of the global blood plasma derivatives market is majorly driven by increase in prevalence of life-threatening disorders, especially hemophilia. Other factors boosting the market growth include rise in adoption of blood plasma derivatives products, upsurge in geriatric population across the world, and increase in awareness about blood & plasma donation. However, factors such as high cost of plasma derivative-based therapy and post-operative risks associated with plasma replacement therapy hamper the market growth. Conversely, the development of enhanced methods for preservation of plasma derivatives along with advanced procedures for fractionation and high potential in untapped markets in the emerging economies are expected to provide lucrative growth opportunities for the market.

Market Segmentation

The global blood plasma derivatives market is segmented based on type, application, end user, and region. On the basis of type, the market is segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. Immunoglobulin segment accounted for the largest market share in 2016, and is expected to continue this trend throughout the forecast period. On the other hand, albumin segment is anticipated to grow at a significant CAGR of 9.4% during the forecast period.

By application, the market is categorized into hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand's Disease (vWD), and other applications. Immunodeficiency diseases segment accounted for the largest market share in 2016, whereas hemophilia segment is expected to register the highest growth rate during the forecast period.

Depending on end user, the market is fragmented into hospitals, clinics, and other end users. Hospitals held the largest share of the market in 2016, whereas clinics segment is expected to register the highest growth rate during the forecast period.

Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA. North America held the largest share of the market in 2016, followed by Europe. On the other hand, Asia-Pacific is anticipated to dominate the market during the analysis period, owing to high population base, increase in disposable income, and improvement in patient awareness about plasma derivatives. Moreover, Asia is a large continent, and has emerged as an epicenter of life-threatening diseases.

Do purchase inquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/656

The key players of this market include Grifols, S.A., SK Plasma Co., Ltd., Fusion Health Care Pvt. Ltd., Biotest AG, Green Cross Corporation, Baxter International Inc., LFB S.A., Octapharma AG, CSL Limited, and Shire Plc.

Other players (these players are not profiled in the report and the same can be included on request) in the value chain include China Biologic Products, Inc., Kedrion Biopharma, Inc., BDI Pharma, Inc., Bayer AG, and Hualan Biological Engineering, Inc.

Blood Plasma Derivatives Market Key Segments:

By Type

- Albumin
- Factor VIII
- Factor IX
- Immunoglobulin
- Hyperimmune Globulin
- Others

By Application

- Hemophilia
- Hypogammaglobulinemia
- Immunodeficiency Diseases
- von Willebrand's Disease (vWD)
- Other Application